TickerTalks
Browse all tickers →
TickerTalks›$ERAS
ERERAS

Erasca, Inc.

$ERAS·$6.4B·Biotechnology·Healthcare
$17.88-0.8%YTD+395.4%1Y+1017.5%
Mentions · last 7 days
2026-08-22: 2 posts2026-08-23: 7 posts55-25%
Price updated 9h ago·X counts updated 8d ago
ERERAS
$ERASErasca, Inc.
$17.88-0.83%55 posts-25%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ERAS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeWinding up for a moveAI verdict · as of 2026-09-01

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Erasca is riding the RAS-approval wave — BlackRock took $388M, ERAS-0015 got FDA Fast Track for PDAC.

Erasca Inc is a clinical-stage oncology company focused on RAS/MAPK pathway cancers — ERAS-0015 (pan-RAS molecular glue for metastatic pancreatic adenocarcinoma) is the lead program. Up 1,018% t12m on the RAS-approval-basket tailwind and the FDA Fast Track designation.

  • The business is pre-revenue: last four quarters printed $0 revenue with EPS from -$0.10 to -$0.60 — this is a pure catalyst-and-partnership story, and analyst FY26 EPS estimate of -$0.95 reflects continued burn.
  • Analyst estimates project modest revenue ramp: FY26 $7.5M, FY27 $375K, FY28 $2.75M — the operating story doesn't drive the tape; the RAS-molecular-glue thesis does.
  • Position sits at the 72nd percentile of the 52-week range with volume 46% above normal — real accumulation into the RAS-basket rotation, and BlackRock's fresh $388M position (Aug 26) is a massive institutional endorsement.
  • The Aug 24 FDA Fast Track Designation for ERAS-0015 in metastatic PDAC is a real regulatory catalyst, and the President R&D Charles Fuchs Aug 12 A-Award of $23.6M reflects executive hiring for the commercial ramp.

The path forward is decided by ERAS-0015 clinical progress in PDAC (Phase 3 design vs Revolution Medicines' 'loose' first-line label), Nov 11 Q3 print for cash burn, and Amgen consolidation-M&A speculation. Another quarter of thin operating progress plus Bernstein Liebhard fiduciary investigation invalidates the coil; a named Big Pharma partnership or clinical data catalyst restarts momentum.

Agrees with X sentimentAligned with the bulls — Revolution Medicines' pan-RAS approval validating tailwind, FDA Fast Track for ERAS-0015 in metastatic PDAC, TNGX-ERAS combo speculation, ERAS as '10x more potent pan RAS glue' making 'major dent in daraxonrasib utilization long term', and Amgen consolidation speculation are all real. The RVMD 'loose' first-line label complicating ERAS's PDAC Phase 3 design is the honest counterweight.

What to watch: ERAS-0015 clinical progress in PDAC (Phase 3 design vs RVMD's 'loose' first-line label complication), the Nov 11 Q3 print for cash burn trajectory, and Amgen consolidation-M&A speculation color. Another quarter of thin operating progress plus Bernstein Liebhard fiduciary investigation invalidates the coil; a named Big Pharma partnership or clinical data catalyst restarts momentum.

On the calendar: 2026-11-11 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment12 posts analyzed · as of 2026-08-31

Talk skews bullish as Erasca gets a validating tailwind from Revolution Medicines' pan-RAS approval alongside its own FDA Fast Track for ERAS-0015 in metastatic pancreatic adenocarcinoma. Bulls flag a potential TNGX-ERAS combo, with one poster arguing the ERAS "x10 more potent pan Ran glue" could "make major dent in daraxonrasib utilization long term", and speculate Amgen may want to consolidate RAS leadership. The debate centers on whether RVMD's "loose" first-line label complicates ERAS's PDAC Phase 3 design.

Read the AI verdict + X sentiment for $ERAS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage oncology biotech targeting RAS/MAPK pathway cancers with small molecule inhibitor combinations.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ERAS.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $ERAS

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-13.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-32.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-77.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-0.14$-0.11-25.7%
Q1 2026May 11, 2026$-0.60$-0.11-438.0%
Q4 2025Mar 12, 2026$-0.10$-0.11+9.1%
Q3 2025Nov 12, 2025$-0.11$-0.110.0%
Next earningsWed, Nov 11·consensus EPS $-0.14

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.60$-27.4M
Q4 FY25$0———$-0.10$-21.7M
Q3 FY25$0———$-0.11$-21.7M
Q2 FY25$0———$-0.12$-20.6M

Forward consensus

5-year forecast · up to 6 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$7.5M$7.5M – $7.5M-$0.95-$0.99 – -$0.895
FY27$375K$375K – $375K-$0.55-$0.67 – -$0.494
FY28$2.8M$2.8M – $2.8M-$0.67-$0.91 – -$0.556
FY29$44.3M$44.3M – $44.3M-$0.78-$0.78 – -$0.785
FY30$281.8M$281.8M – $281.8M-$0.38-$0.38 – -$0.383

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.72%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-1.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+42.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 222.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.655-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellApr 1Ebun GarnerChief Legal Officer80.0K sh$1.3M
+ 8 other (7 awards · 1 exempt) in window

See when $ERAS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 123
AI summary

Charles S. Fuchs filed an initial Form 3 disclosing his insider status as President, R&D at Erasca, Inc., effective August 10, 2026. The filing confirms his appointment to an officer role at the oncology-focused biotech. No securities are currently beneficially owned, meaning no equity stake was disclosed at the time of filing. Form 3 filings are required within 10 days of becoming a Section 16 reporting person.

8-KOfficer or director changeAug 108-K — Item 5.02: Officer or director change
AI summary

Erasca, Inc. (ERAS), a clinical-stage oncology company focused on RAS/MAPK pathway cancers, appointed Charles S. Fuchs, M.D., M.P.H. as President, Research & Development, effective August 10, 2026. Dr. Fuchs, 66, brings over three decades of distinguished oncology leadership, including stints as CMO of Tubulis GmbH (subsequently acquired by Gilead), SVP and Global Head of Oncology and Hematology at Genentech and Roche, Director of Yale Cancer Center, and professor at Harvard Medical School. His appointment with no pre-existing arrangement or family relationship to existing officers follows standard SEC disclosure requirements for named executive officers. This high-caliber hire is significant for investors as it signals Erasca's commitment to accelerating and strengthening its clinical pipeline with world-class scientific and drug development leadership.

424B5Prospectus supplement (offering)Jul 14424B5
AI summary

Erasca (ERAS) — 424B5 final prospectus supplement for the sale of 31,428,572 shares at $17.50 per share, with a $1.05 per-share underwriting discount, generating approximately $517 million in gross proceeds. Shares settle and deliver on approximately July 15, 2026. Material — confirms the pricing and settlement of Erasca's ~$517M equity offering; dilutive for existing shareholders.

424B5Prospectus supplement (offering)Jul 13424B5
AI summary

Erasca (ERAS) — 424B5 prospectus supplement (July 13 filing version) for the sale of 31,428,572 shares at $17.50, with underwriters purchasing at $16.45. This is an earlier iteration of the same equity offering finalized on July 14. Material — confirms Erasca's dilutive ~$550M equity raise is proceeding under its automatic shelf registration.

S-3ASRAuto-shelf registrationJul 13S-3ASR
AI summary

Erasca (ERAS) — S-3ASR automatic shelf registration statement filed July 13, 2026. This shelf enables Erasca to offer and sell various securities from time to time on an expedited basis. The shelf was filed in connection with the contemporaneous ~$550M equity offering. Administrative — enabling shelf registration; the actual offering terms are in the concurrent 424B5 prospectus supplement.

8-KShareholder voteJul 18-K — Item 5.07: Shareholder vote
AI summary

Erasca held its 2026 Annual Meeting; specific vote details are not visible in the excerpt which cuts off at the cover page. Annual meeting voting results — administrative disclosure.

8-KPress release / Reg FDApr 278-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

ERAS filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-04-27. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

+ 21 other (6 13Gs · 5 routine 8-Ks · 3 earnings 8-Ks · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Dutynewsfilecorp.com·6d agoBlackRock Inc. Takes $387.54 Million Position in Erasca, Inc. $ERASdefenseworld.net·6d agoAlger Mid Cap 40 ETF Q2 2026 Portfolio Reviewseekingalpha.com·7d agoErasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinomaglobenewswire.com·8d agoERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Dutynewsfilecorp.com·14d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 9 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport